72 cases of clinical observation on curing acute cerebral infarction (ACI) using traditional Chinese medicine (TCM) injection syndrome differentiation

Objective To study the efficacy and safety of treatment for both root cause and symptoms by combining Activating Blood Circulation and Removing Blood Stasis Therapy with traditional Chinese medicine injection. Methods 120 patients with acute cerebral infarction were recruited in the study, and the patients were classified into control group and treatment group randomly. There were three subgroups in the treatment group: 35 patients were diagnosed as deficiency of vital energy and blood stasis, 21 patients as phlegm and blood stasis, and 16 patients as toxic-heat and blood stasis. Based on the regular treatment with western medicine, the control group were prescribed with Xuesaitong freeze-dried powder; the group with deficiency of vital energy and blood stasis was prescribed with Astragalus mongholicus injection and Xuesaitong freeze-dried powder; the group with phlegm and blood stasis received injection of Gastrodin and injection of Ligustrazine; and the group with toxic-heat blood stasis additionally received Qingkailing freeze-dried powder and salvia miltiorrhiza. Results Activating Blood Circulation and Removing Blood Stasis Therapy (ABCRBS Therapy) as an essential clinical approach should be applied in the whole course of the cerebral infarction treatment. According to the research results, the total effective rates, traditional Chinese medicine syndrome efficacy and nerve function deficit efficacy of treatment groups were better than those of control group (P0.05); the traditional Chinese medicine syndrome score and nerve function deficit score of the treatment group were more effectively improved than those of the control group (P0.05). As for improving the hemorheology indexes such as hematocrit, whole blood viscosity aggregation index plasma fibrinogen, plasma viscosity and erythrocyte deformation index, the treatment group was also better than the control group (P0.05). Conclusions Treatment with both root cause and symptoms by combining ABCRBS Therapy with TCMI has advantages of safety and efficacy.